SecBot SecBot
8-K ·Filed Jul 20, 2026

PSNL

Personalis, Inc.
NEUTRAL
Impact 6/10
Horizonmonths Processed3mo ago SEC0001193125-26-309101
8-K Item 1.01 + 5.02 (likely routine officer/director compensation agreement)
Actionable Insight • Neutral

Monitor PSNL stockholder vote and regulatory filings (HSR, Form S-4). The stock will likely trade near the implied deal value, which depends on Tempus's stock price. Key risk is deal failure or extended timeline. Watch for any competing bids or shareholder litigation.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$13.44
T+0 close · Jul 20, 2026 · via day close
Latest settled
+17.93%
T+60 · $15.85
Vs SPY
+13.96%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 21 $13.44entry
  2. T+1 · 4mo ago −7.22%α −7.10% · $12.47
  3. T+5 · 4mo ago −10.86%α −9.63% · $11.98
  4. T+20 · 3mo ago +3.50%α +0.94% · $13.91
  5. T+60 · 5w ago +17.93%α +13.96% · $15.85
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Personalis (PSNL) entered into a definitive merger agreement with Tempus AI (TEM) on July 20, 2026. PSNL shareholders will receive Tempus Class A common stock based on a variable exchange ratio (floor of 0.3356 if TEM ≤ $48.42, otherwise $16.25 / TEM VWAP), with Tempus having the option to pay cash for up to 50% of shares at $16.25 per share. The deal, structured as a tax-free reorganization, requires PSNL stockholder approval, HSR clearance, and other customary conditions, with a termination fee of ~$76.8 million each way. Merck, holding ~13% of PSNL, has agreed to vote in favor via a voting agreement.

Key Financial Metrics

Deal Type
merger

Key Facts

  • Merger consideration: Tempus Class A common stock with exchange ratio = 0.3356 if TEM ≤ $48.42, else $16.25 / TEM VWAP; Tempus may elect cash for up to 50% of shares at $16.25/share
  • Merck Sharp & Dohme LLC, holding ~13% of PSNL, entered into a voting agreement to support the deal
  • Termination fee of approximately $76.8 million payable by either party under specified circumstances
  • Conditions include PSNL stockholder approval, HSR waiting period expiration, effectiveness of Form S-4, and tax opinion
  • Outside Date initially April 20, 2027, with automatic six-month extensions up to April 20, 2028
  • PSNL board unanimously approved and recommends adoption; received fairness opinions from Centerview Partners and TD Cowen

Financial Impact

Per-share consideration of $16.25 in cash (if elected) or Tempus stock with a floor of 0.3356x; total equity value implied by shares outstanding (~106.8M) is approximately $1.7B at the cash election price, but actual value is variable based on Tempus stock price

share pricedilutionownership structure

Risk Factors

  • Failure to obtain PSNL stockholder approval (majority of outstanding shares required)
  • Regulatory delays or antitrust challenges under HSR Act
  • Tempus stock price decline reducing the value of stock consideration
  • Termination by either party under specified conditions, triggering break fees

Market Snapshot

Exchange
Nasdaq
Sector
Services-Medical Laboratories
Analyst Consensus
85% bullish (13 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-309101
Document: d64399d8k.htm0001193125-26-309101
Document: d64399dex101.htm0001193125-26-309101
Document: 0001193125-26-309101-index-headers.html0001193125-26-309101
Document: 0001193125-26-309101-index.html0001193125-26-309101
Document: 0001193125-26-309101.txt0001193125-26-309101

Track record

29 reports on PSNL

Performance horizon

4 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +18.82% at T+60 after the Jul 20, 2026 report. 8 of 9 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $15.16 Now $14.80 −2.34% settles Feb 12
  2. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $15.71 Now $14.80 −5.79% settles Feb 11
  3. Nov 12, 20264d ago 425 Neutral 4/10 Entry $15.86 Now $14.80 −6.68% settles Feb 10
  4. Nov 6, 202610d ago 425 Neutral 3/10 Entry $15.95 Now $14.80 −7.21% settles Feb 5
  5. Nov 4, 202612d ago 8-K Neutral 5/10 Entry $15.55 Now $14.80 −4.82% settles Feb 3
  6. Nov 3, 202613d ago 425 Neutral 3/10 Entry $15.79 Now $14.80 −6.27% settles Feb 2
  7. Oct 30, 202617d ago 425 Neutral 4/10 Entry $15.76 Now $14.80 −6.09% settles Jan 29
  8. Oct 21, 202626d ago DEFM14A Neutral 5/10 Entry $15.82 Now $14.80 −6.45% settles Jan 20
  9. Oct 20, 202627d ago 425 Neutral 4/10 Entry $15.90 Now $14.80 −6.92% settles Jan 19
  10. Oct 20, 202627d ago 425 Neutral 5/10 Entry $15.90 Now $14.80 −6.92% settles Jan 19
Showing 10 of 29

US Market Status

Market Closed · Opens in 8h 47m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 20, 2026